Abstract
Background Phenotyping allergic rhinitis (AR) by IgE sensitivity and presence of comorbidities may help characterize allergic diseases, provide a clinical framework to inform treatment decisions, and improve clinical trial design. MP-AzeFlu (137µg azelastine hydrochloride + 50 µg fluticasone propionate intranasal spray) is a treatment for AR but the effectiveness of MP-AzeFlu on disease severity by AR phenotypes is unknown. This prospective, noninterventional study evaluated the effectiveness of MP AzeFlu (1 spray in each nostril twice daily for 2 weeks) across novel AR phenotypes.
Original language | English |
---|---|
Publication status | Published - 6 Jun 2020 |
Event | EAACI Digital Congress 2020 - Digital, London, United Kingdom Duration: 6 Jun 2020 → 8 Jun 2020 |
Conference
Conference | EAACI Digital Congress 2020 |
---|---|
Country/Territory | United Kingdom |
City | London |
Period | 6/06/20 → 8/06/20 |